The present invention relates to a sunscreen formulation comprising at least one of the UV filters (A) selected from (a) triazine derivatives; (b) cinnamic acid derivatives; (c) bis-resorcinyl triazines; (f) benzimidazole derivatives; (is) 4-Methylbenzylidene Camphor; (h) benzoyl piperazine derivatives; (j) benzoxazole derivatives; (k) diarylbutadiene derivatives; (I) phenyl benzotriazole derivatives; (n) benzylidene malonates; (o3) TEA-Salicylate; (r) imidazoline derivatives; (u) inorganic UV filters selected from metal oxides; (v) naphthalates; and (w) merocyanine derivatives; and optionally comprising at least one of the UV filters (B) selected from (d) aminobenzophenone derivatives; (e) dibenzoylmethane derivatives; (g) β,β-Diphenylacrylate derivatives; (i5) camphor derivatives different from; (o3) salicylate derivatives different from; (p) anthranilate derivatives; and (s) benzalmalonate derivatives; wherein the ratio R of the effective irradiance for previtamin D3 formation Epvd to the effective irradiance for erythema formation Eer on the skin is at least 1.8, for increasing the transmittance of UV radiation on human skin for the production of cholecalciferol (previtamin D3) and simultaneously for the use in a method for protecting the human skin against UV radiation when exposed to the sun, which method comprises applying said sunscreen formulation to the skin.La présente invention concerne une formulation d'écran solaire comprenant au moins l'un des filtres UV (A) choisis parmi (a) des dérivés de triazine ; (b) des dérivés d'acide cinnamique ; (c) des bis-résorcinyl-triazines ; (f) des dérivés de benzimidazole ; (i5) 4-méthylbenzylidène camphre ; (h) des dérivés de benzoyle pipérazine ; (j) des dérivés de benzoxazole ; (k) des dérivés de diarylbutadiène ; (I) des dérivés de phényl-benzotriazole ; (n) des malonates de benzylidène ; (o3) TEA-salicylate ; (r) des dérivés d'imidazoline ; (u) des filtres UV inorganiques choisis parmi des oxydes métalliques ; (v)